Pre-clinical studies had consistently demonstrated that the beneficial effects of GLP-1 agonists in osteoarthritis was primarily mediated by inhibiting the NF-κB pathway [21,22,25]. The gene discussed is GLP1R; the disease is osteoarthritis.